Is Astrotech a Good Aerospace Stock to Add to Your Portfolio?

NASDAQ: ASTC | Astrotech Corporation News, Ratings, and Charts

ASTC – Commercial equipment manufacturer for aerospace defense, Astrotech (ASTC), is suffering depressed profit margins and stock price momentum given the slump in the global airline industry. But the question is, as domestic and international travel picks up in the coming months as expected, will ASTC be able to generate adequate profits to justify its current valuation? Read more to find out.

Commercial equipment manufacturer Astrotech Corporation (ASTC) operates in the aerospace and defense sector. The slump in the travel and aerospace industry has severely affected ASTC. The stock has declined 62.1% over the past year, and 32.8% year-to-date.

Airports are currently struggling to stay afloat amid depressed air traffic and huge overhead costs. As a result, most airports are likely to postpone capital investments to buy or upgrade their existing non-current assets. The potential fourth wave of coronavirus has exacerbated the situation, causing shares of ASTC to slump 46.4% over the past month.

Here’s what we think could shape ASTC’s performance in the near term:

Depressed Demand

Austin, Tex.-based ASTC, which manufactures explosive and narcotics trace detectors that are used primarily in airports and secured facilities, has been witnessing a slump in demand given lower air traffic. Because domestic and international travel remains low amid a fourth COVID-19 infection wave, the demand for ASTC’s products is likely to remain depressed in 2021. Also, as international travel continues to be depressed amid surging coronavirus cases worldwide, the sales of ASTC’s flagship product TRACER 1000 sales might decline too.

Furthermore,  given that ASTC’s products used for explosives and narcotics detection are non-current assets, the demand and sales margins for them  are likely to remain low because  most airports already possess the required equipment. Also, as the United States moves toward the widespread decriminalization  of marijuana, the demand for its AgLAB-1000-D2 hemp and cannabis detector might decline  in the near future.

ASTC’s latest breath analyzer product, BreathTest-1000, is under development, and will require FDA approval for commercial use. In this regard, ASTC noted  in its latest quarterly earnings release that “Obtaining FDA approval is a complex and lengthy process, and there can be no assurance that FDA approval for BreathTest-1000 will be granted on a timely basis or at all.”

Weak Financials

Despite having a market capitalization of $35.57 million, ASTC’s trailing-12-month revenues came in at $552,000. The company generated $58,000 in gross profits last year, translating to a gross profit margin of 10.5%. However, ASTC’s trailing-12-month gross profit margin is 63.4% lower than the industry average 28.7%. Its trailing-12-month net income stood at negative $7.89 million, implying a negative return on sales, while its trailing-12-month EBITDA stood at negative $6.70 million. Also, the company’s trailing-12-month ROE, ROA and ROTC are negative.

ASTC is bleeding cash from its operations, as evidenced by  its negative cash flows. The company’s trailing-12-month net operating cash flow and levered free cash flow were negative $6.07 million and $2.92 million, respectively. With negative cash flows and operating profits, ASTC’s  creditworthiness is questionable . Its debt/free cash flow is negative. Without proper cash inflows to pay off $3.17 million in  outstanding, ASTC’s  debt and interest  burden is  immense.

Stretched Valuation

In terms of trailing-12-month EV/sales, ASTC is currently trading at 30.10x, significantly higher than the industry average  2.15x. The stock’s trailing-12-month price/sales multiple of 24.89 is 1,377.5% higher than the industry average  1.68.

POWR Ratings Reflect Bleak Outlook

ASTC has an overall D rating, which equates to Sell in our proprietary POWR Ratings system. The POWR Ratings are calculated considering 118 different factors, with each factor weighted to an optimal degree.

ASTC has a D grade for Quality and Value, and F for Stability. Along with negative profitability and relative overvaluation, ASTC has a beta of negative 1.22, indicating an inverse relationship with the market movements. These justify ASTC’s grades.

Of the 66 stocks in the C-rated Air/Defense Services industry, ASTC is ranked #61. In addition to the grades we’ve highlighted, one  can check out ASTC Ratings for Momentum, Growth, and Sentiment here.

There are 17 stocks in the Air/Defense services industry with an overall rating of B. Click here to view them.

Bottom Line

ASTC’s beta indicates that the stock moves in the opposite direction to  current market trends. As the equity markets rally amid a faster-than-expected economic recovery, ASTC stock will likely  decline further. Thus, we think the stock is best avoided now.


ASTC shares were trading at $1.19 per share on Wednesday morning, down $0.00 (-0.42%). Year-to-date, ASTC has declined -32.77%, versus a 10.91% rise in the benchmark S&P 500 index during the same period.


About the Author: Aditi Ganguly


Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do’s and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ASTCGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


How Low Could Stocks Go?

The S&P 500 (SPY) is starting to test key support levels for the first time since November 2023 given continuing signs that Fed rate cuts are getting pushed further and further into the future. This begs the question of “how low could stocks go?” 44 year investment veteran Steve Reitmeister does his level best to answer that question including a trading plan and top picks to stay one step ahead of the market. Read on below for the full story...

3 Biotech Stocks to Buy to Power Through April

The biotech sector is primed for growth, fueled by a surge in FDA approvals, anticipated M&A deals, and the integration of AI in drug discovery. So, fundamentally sound biotech stocks Theratechnologies (THTX), Harmony Biosciences (HRMY), and Shionogi & Co. (SGIOY) might be solid buys in this month. Keep reading...

Check out These 3 Internet Stocks for Potential Gains

Amplified internet usage, technological advancements, and a rising digital transformation worldwide have driven the internet industry rapidly. To that end, quality internet stocks Wix.com (WIX), Tripadvisor (TRIP), and Yelp (YELP) could be solid buys now. Read on…

Top 3 Financial Services Stocks With Unstoppable Momentum

The financial services sector is set for solid growth owing to global economic trends, technological advancements making digital services more accessible, and changing consumer preferences.Therefore, investors could consider buying fundamentally strong financial services stocks Broadridge Financial Solutions (BR), Banco Macro (BMA), and Yiren Digital (YRD) as they look well-positioned to continue their momentum. Read more...

Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

Read More Stories

More Astrotech Corporation (ASTC) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ASTC News